DUBLIN--(BUSINESS WIRE)--The "Anaplastic Oligoastrocytoma - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
This latest pipeline guide provides comprehensive information on the therapeutics under development for Anaplastic Oligoastrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Oligoastrocytoma and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II and Phase I stages are 4 and 3 respectively.
- AbbVie Inc
- Astellas Pharma Inc
- Boehringer Ingelheim GmbH
- Novartis AG
- Pfizer Inc
Key Topics Covered
- Report Coverage
- Anaplastic Oligoastrocytoma - Overview
- Anaplastic Oligoastrocytoma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Anaplastic Oligoastrocytoma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Anaplastic Oligoastrocytoma - Companies Involved in Therapeutics Development
- Anaplastic Oligoastrocytoma - Drug Profiles
For more information about this report visit https://www.researchandmarkets.com/research/8q8w8c/2018_pipeline?w=4